Intellia Therapeutics is a genome editing company focused on developing therapeutics using CRISPR/Cas9 technology. CRISPR/Cas9, an acronym for Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated 9 (Cas9), is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid (DNA). To realize the transformative potential of CRISPR/Cas9-based technologies, Co. is building a range of genome editing company, by utilizing its modular platform, to advance in vivo and ex vivo therapies for diseases with high unmet need. We show 33 historical shares outstanding datapoints in our NTLA shares outstanding history coverage, used to compute NTLA market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing NTLA market cap history over the course of time is important for investors
interested in comparing NTLA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of NTLA versus a peer is one thing; comparing
NTLA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like NTLA can fluctuate over the course of history.
With this page we aim to empower investors researching NTLA by allowing them to research the NTLA market cap history. |
Free NTLA Email Alerts:
Video: The Importance of Market Cap
